Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-007 · synthetic case CVR-FX-25
Secondary prevention at goal
LDL-C 48 in very high risk.
Purpose: LDL-C 48 in very high risk.
Inputs the engine received
Lipids and risk estimate
- LDL-C
- 48 mg/dL
Patient
- Age
- 71 years
- Established ASCVD
- Yes
- Major ASCVD events
- 2
- High-risk conditions
- 3
Treatment and familial risk
- On lipid-lowering therapy
- Yes
- Months since last LDL-C
- 5 months
What the engine reports
Detected clinical pattern
Established ASCVD — Very High Risk
Two or more major events, or one major event with two or more high-risk conditions.
- Category: Secondary prevention · very high risk
Why this pattern was identified
- Established ASCVD. Very high risk: two or more major ASCVD events, or one major event with two or more high-risk conditions.
Recommended next steps
For physician consideration. Urgent review always comes first.
- 1Consider a one-time Lp(a) measurement.ESC/EAS 2019; listed as an enhancer by ACC/AHA 2018.
Evidence and rule trace · 2 rules
CV-01Established ASCVD
Inputs: established ASCVD · 2 major event(s) · 3 high-risk condition(s)
Secondary prevention, very high risk.
CV-06Lipoprotein(a)
Inputs: Lp(a) never measured
One-time measurement is recommended by several societies.
Evidence
- EV-ACCAHA-CHOL-2018 · Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
- EV-ACC-ECDP-2022 · Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk. J Am Coll Cardiol. 2022;80(14):1366-1418.
- EV-ESC-EAS-2019 · Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.
Physician adjudication required. Clinical decision support for physician review. This output organizes guideline categories and risk modifiers. It does not calculate a 10-year risk, select a drug or dose, or replace a shared decision with the patient. Physician adjudication is required.
Change the values
The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.
10-year risk category (Pooled Cohort Equations)
○ Low · <5%
Lifestyle emphasis
○ Borderline · 5 to <7.5%
Enhancers inform the discussion
○ Intermediate · 7.5 to <20%
Statin discussion favored; CAC can help
○ High · ≥20%
Statin benefit is greatest
No stage is assigned for the values entered.
Lipids and risk estimate
- <100
- 100–159
- 160–189
- ≥190
- <150
- 150–499
- ≥500
- ≥1000
This engine does not calculate it.
Patient
Recent ACS, prior MI, ischemic stroke, symptomatic PAD.
Age ≥65, HeFH, prior revascularization, diabetes, hypertension, CKD, smoking, HF.
Risk enhancers and extra tests
Treatment and familial risk
More cardio cases
CVR-FX-01
Prior myocardial infarction, LDL-C 88 on a statin
Secondary prevention, not very high risk.
CVR-FX-02
Very high risk with LDL-C 62 on maximal therapy
Two events: the threshold is 55.
CVR-FX-03
LDL-C 205 and tendon xanthomas
Severe hypercholesterolemia.
CVR-FX-04
Diabetes at 58 with LDL-C 110
A guideline statin group.
CVR-FX-05
Intermediate risk 12% with enhancers
Family history and an hs-CRP of 3.4.
CVR-FX-06
Borderline risk 6.0%, no enhancers
Nothing to push the decision either way.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.